Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells

Immunology

Volumn 133, Issue 1, 2011, Pages 62-73

  Hamann, Isabell ^a   Unterwalder, Nadine ^b   Cardona, Astrid E ^c   Meisel, Christian ^b   Zipp, Frauke ^d   Ransohoff, Richard M ^e   Infante Duarte, Carmen ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; CX3CR1; Natural killer cell maturation; Natural killer cell phenotypes; Natural killer cells

Indexed keywords

CD27 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CYTOKINE; INTERLEUKIN 2; L SELECTIN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR KIR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKP30; NATURAL KILLER CELL RECEPTOR NKP46; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; MONOCYTE; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

CELL SEPARATION; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; PHENOTYPE; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953296839     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03409.x     Document Type: Article

References (45)

1. Cardona AE, Ransohoff RM. Chemokine receptor CX3CR1. UCSD-Nat Mol Pages 2009; doi:10.1038/mp.a000633.01.
2. Fraticelli P, Sironi M, Bianchi G et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107:1173-81.
3. + cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168:6173-80.
4. Dichmann S, Herouy Y, Purlis D, Rheinen H, Gebicke-Harter P, Norgauer J. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res 2001; 50:529-33.
5. Moatti D, Faure S, Fumeron F et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97:1925-8.
6. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89:401-7.
7. Landsman L, Bar-On L, Zernecke A et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113:963-72.
8. Tuo J, Smith BC, Bojanowski CM, Meleth AD, Gery I, Csaky KG, Chew EY, Chan CC. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J 2004; 18:1297-9.
9. Tuo J, Bojanowski CM, Zhou M et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48:3827-36.
10. Simeoni E, Vassalli G, Seydoux C, Ramsay D, Noll G, von Segesser LK, Fleury S. CCR5, RANTES and CX3CR1 polymorphisms: possible genetic links with acute heart rejection. Transplantation 2005; 80:1309-15.
11. Cao G, Lu Y, Gao R, Xin Y, Teng D, Wang J, Li Y. Expression of fractalkine, CX3CR1, and vascular endothelial growth factor in human chronic renal allograft rejection. Transplant Proc 2006; 38:1998-2000.
12. Umehara H, Tanaka M, Sawaki T et al. Fractalkine in rheumatoid arthritis and allied conditions. Mod Rheumatol 2006; 16:124-30.
13. Murphy G, Caplice N, Molloy M. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford) 2008; 47:1446-51.
14. Bolovan-Fritts CA, Spector SA. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2008; 111:175-82.
15. Soriano SG, Amaravadi LS, Wang YF et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002; 2:59-65.
16. Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation 2005; 2:17.
17. Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 2003; 2:65-70.
18. Cardona AE, Pioro EP, Sasse ME et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9:917-24.
19. Huang D, Shi FD, Jung S et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20:896-905.
20. Infante-Duarte C, Waiczies S, Wuerfel J, Zipp F. New developments in understanding and treating neuroinflammation. J Mol Med 2008; 86:975-85.
21. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006; 29:518-27.
22. Morandi B, Bramanti P, Bonaccorsi I, Montalto E, Oliveri D, Pezzino G, Navarra M, Ferlazzo G. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008; 57:1-5.
23. Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009; 21:634-40.
24. Infante-Duarte C, Weber A, Kratzschmar J et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 2005; 19:1902-4.
25. Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006; 67:170-82.
26. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007; 110:606-15.
27. bright subset. Blood 2001; 97:3146-51.
28. Vossen MT, Matmati M, Hertoghs KM et al. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol 2008; 180:3739-45.
29. dim NK cells. Blood 2010; 116:1299-307.
30. dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64.
31. + NK-cell subset. Blood 2010; 116:3865-74.
32. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998; 161:5821-4.
33. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40.
34. Zhang AL, Colmenero P, Purath U et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007; 110:2484-93.
35. bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997; 27:354-60.
36. dim human NK-cell subsets. Blood 2010; 115:274-81.
37. Barlic J, Sechler JM, Murphy PM. IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood 2003; 102:3494-503.
38. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001; 167:3129-38.
39. Habib T, Nelson A, Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003; 112:1033-45.
40. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002; 72:856-63.
41. de Rham C, Ferrari-Lacraz S, Jendly S, Schneiter G, Dayer JM, Villard J. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther 2007; 9:R125.
42. 1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. J Neuroimmunol 2002; 2:46-55.
43. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-β1. J Immunol 1995; 155:1066-73.
44. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136:3916-20.
45. Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008; 112:1776-83.